A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs SAR 440340 (Primary) ; Corticosteroids
- Indications Chronic obstructive pulmonary disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 01 Nov 2019 Planned number of patients changed from 340 to 850.
- 12 Sep 2019 Planned primary completion date changed from 1 Dec 2019 to 2 Oct 2019.
- 25 Apr 2019 Planned End Date changed from 1 Apr 2020 to 19 Feb 2020.